p16/Ki-67染色、HPV E6/E7mRNA和联合检测对HSIL+病变诊断的临床价值

来源期刊：广州医药 | 17-21 发布时间：2021-11-25 收稿时间：2025/11/13 18:11:18 阅读量：7

作者：: 简凤萍,

罗燕艳,

徐秀梅,

邓文同,

梁锐根,

关键词：: p16 Ki-67 人乳头瘤病毒 E6/E7mRNA 宫颈上皮内瘤低度/高度病变; p16 Ki-67 antigen Human papillomavirus E6/E7mRNA Low/high grade lesions of cervical intraepithelial neoplasia LSIL/ HSIL

DOI：: 10.3969/j.issn.1000-8535.2021.02.004

收稿时间：: 2020-10-03
修订日期：
接收日期：
引用总数：: 0

目的探讨p16/Ki-67染色、HPV E6/E7mRNA和联合检测对HSIL+病变诊断的临床价值。方法募集2017年3月—2020年8月期间,于中山市博爱医院妇产科就诊,组织学证实为宫颈炎患者209例、LSIL患者169例、HSIL患者131例和宫颈癌患者86例作为研究对象,回顾分析研究对象术前细胞学样本p16/Ki-67染色、HPV E6/E7mRNA检测结果,纵向比较p16/Ki-67染色、HPV E6/E7mRNA和联合检测在不同级别宫颈病变的阳性率的差异,横向比较p16/Ki-67染色、HPV E6/E7mRNA和联合检测在相同宫颈病变的阳性率的差异,综合评估p16/Ki-67染色、HPV E6/E7mRNA和联合检测诊断HSIL+病变效能的差异。结果 ①纵向比较:p16/Ki-67染色、HPV E6/E7mRNA和联合检测阳性率随宫颈病变程度的加重呈趋势性升高(p16/Ki-67染色:χ²=374.34,P<0.001;HPV E6/E7mRNA检测:χ²=289.21,P<0.001;联合检测:χ²=343.90,P<0.001)。②横向比较:在宫颈炎、LSIL、宫颈癌组,p16/Ki-67染色、HPV E6/E7mRNA和联合检测阳性率之间差异均不具有统计学意义(均P>0.05)。在HSIL组,p16/Ki-67染色和联合检测之间阳性率差异有统计学意义(χ²=8.09,P=0.004); HPV E6/E7mRNA和联合检测之间阳性率差异有统计学意义(χ²=11.30,P=0.001)。③p16/Ki-67染色、HPV E6/E7mRNA和联合检测诊断HSIL+的灵敏度,总体差异有统计学意义(χ²=7.69,P=0.021)。p16/Ki-67染色与联合检测法之间的灵敏度差异有统计学意义(χ²=7.29,P=0.007);HPV E6/E7mRNA检测与联合检测法之间的灵敏度差异有统计学意义(χ²=4.84,P=0.028)。p16/Ki-67染色、HPV E6/E7mRNA和联合检测诊断HSIL+的特异度及符合率的总体差异不具有统计学意义(χ²₁=5.38,P₁=0.068;χ²₂=0.93,P₂=0.628)。结论 p16/Ki-67染色、HPV E6/E7mRNA 和联合检测均可有效筛出HSIL+病变,但是联合检测能显著提高HSIL+病变诊断的灵敏度,降低漏诊率,同时保持了较好的特异度和符合率,建议将p16/Ki-67染色和HPV E6/E7mRNA联合检测作为早期诊断HSIL+病变的策略。

Objective To investigate the clinical value of p16/Ki-67 staining E6/E7 mRNA and combined detection in the diagnosis of HSIL+ lesions. Methods From March 2017 to August 2020,209 cases of cervicitis,169 cases of LSIL,131 cases of HSIL and 86 cases of cervical cancer confirmed by histology were selected as the research objects. The results of p16/Ki-67 staining and HPV E6/E7 RNA detection of the preoperative cytological samples were retrospectively analyzed and the p16/Ki-67 staining and HPV E6/E7 mRNA detection results were compared longitudinally. The positive rates of E6/E7mRNA and combined detection in different grades of cervical lesions were compared.The positive rates of p16/Ki-67 staining,HPV E6/E7 mRNA and combined detection in the same cervical lesions were compared horizontally.The differences in the diagnostic efficacy of p16/Ki-67 staining,HPV E6/E7 mRNA and combined detection in the diagnosis of HSIL+lesions were comprehensively evaluated. Results ①Longitudinal comparison:the positive rates of p16/ Ki-67 staining, HPV E6/E7mRNA and combined detection increased with the severity of cervical lesions(p16/Ki-67 staining:χ²=374.34,P<0.001;HPV E6/E7 mRNA detection:χ²=289.21,P<0.001;joint detection:χ²=343.90,P<0.001). ②Transverse comparison: in cervicitis, LSIL and cervical cancer groups,there were no significant differences in the positive rates of p16/Ki-67 staining, HPV E6/E7 mRNA and combined detection (all P>0.05). In the HSIL group,there was significant difference in the positive rate between p16/Ki-67 staining and combined detection (χ²=8.09,P=0.004)and the difference between HPV E6/ E7 mRNA and combined detection was statistically significant(χ²=11.30,P=0.001). ③The sensitivity of p16/Ki-67staining,HPV E6/E7 mRNA and combined detection in the diagnosis of HSIL+ was statistically significant(χ²=7.69,P=0.021). The sensitivity difference between p16/Ki-67 staining and combined detection was statistically significant(χ²=7.29,P=0.007);the sensitivity difference between HPV E6/E7 mRNA detection and combined detection method was statistically significant (χ²=4.84,P=0.028). There was no significant difference in the specificity and coincidence rate of p16/Ki-67 staining,HPV E6/E7 mRNA and combined detection in the diagnosis of HSIL+(χ²₁=5.38,P₁=0.068;χ²₂=0.93,P₂=0.628). Conclusion P16/Ki-67 staining,HPV E6/E7 mRNA and combined detection may effectively screen out HSIL+ lesions,reduce the missed diagnosis rate, but the combined detection may significantly improve the sensitivity of diagnosis of HSIL+ lesions, while maintaining good specificity and coincidence rate.It is suggested that p16/Ki-67 staining and HPV E6/E7 mRNA detection should be used as a strategy for early diagnosis of HSIL+ lesions.

1、李晓林,袁文娟,陈龙,等. 高危型HPV E6/E7mRNA检测在宫颈机会性筛查中应用价值研究[J].中华肿瘤防治杂志,2017,24(4):217-222.

2、王茂,贾伟,王宏. p16/Ki-67表达水平与宫颈病变及HPV感染的关系分析[J].临床和实验医学杂志,2018,17(24):2652-2655.

3、 LIU T Y,XIE R,LUO L,REILLY K H,et al. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples[J].J Virol Methods,2014,196(1):120-125.

4、 DANIELA G,PAOLO G R,ELENA C,et al. Use of Cytology,E6/E7 mRNA and p16INK4a-Ki-67 to define the management of human papillomavirus (HPV)-positive women in cervical cancer screening[J].Am J Clin Pathol,2016,145(1):35-45.

5、陈飞,任琛琛,杨立,等. HPV E6/E7 mRNA,p16/Ki67检测在ASCUS中的诊断价值[J].现代妇产科进展,2019,28(1):54-57.

6、刘玉艳,沈久洋,朱安超,等. p16/Ki-67细胞学双染在子宫颈癌筛查中应用价值[J].临床与实验病理学杂志,2017,33(1):38-41.

7、方三高,石群立,周晓军,等. 解读2014年WHO女性生殖器官肿瘤分类(宫颈)[J].重庆医学,2015,28(1):7-17.

8、 CELEWICZ A,CELEWICZ M,WEOWSKA M,et al. Clinical efficacy of p16/Ki-67 dual-stained cervical cytology in secondary prevention of cervical cancer[J].Pol J Pathol,2018,69(1):42-47.

9、 ZIEMKE P,GRIESSER H. Indications for p16/Ki-67 in cervical cytology[J].Pathology,2017,38(1):38-44.

10、中华医学会. 临床技术操作规范病理学分册[M].北京: 人民军医出版社,2012: 33.

11、卢朝辉,陈杰. WHO女性生殖器官肿瘤学分类(第4版)解读[J].中华病理学杂志,2014,43(10):649-650.

12、穆启梅,郭珍,周欢欢,等. 液基薄层细胞检查、HPV-DNA分型在宫颈癌筛查中的应用价值[J].中国妇幼保健,2018,33(3):528-530.

13、赵培玉,陈敖峥,秦锦龙,等. Cervista HR-HPV DNA检测联合TCT在宫颈癌筛查中的临床价值[J].检验医学,2017,32(4):322-325.

14、杨文蕾,狄江丽,田甜,等. 中国3省妇女宫颈癌防治知信行现况调查及影响因素分析[J].中国健康教育,2017,33(10):876-880.

15、刘倩,王玮. 浅谈宫颈癌临床治疗新进展[J].实用医学杂志,2018,34(1):5-7.

16、 SAWAYA G F,SMITH-MCCUNE K,KUPPERMANN M. Cervical cancer screening: more choices in 2019[J].JAMA,2019,321(20):2018.